There is growing recognition that we must advocate to ensure that CV patients in the United States can gain more timely access to medical, interventional, and surgical innovations shown to be effective and safe. In parallel, we need to advance comparative effectiveness and health services research.
To date, efforts by the College to engage federal policymakers in the area of medical research and innovation policy have been sporadic and focused on particular areas of interest. Given the current climate for research funding, and amid real concerns that the United States is lagging in its efforts, it is imperative that the College bring a strategic and organized approach to these issues. To effect change, it is important to identify key areas where the ACC can have the greatest impact, taking advantage of its member base, scientific expertise, and focus on quality improvement.
At the request of the Advocacy Steering Committee, we undertook an effort to identify strategic areas of interest to the College, its members, and patients.
Based on interviews with experts from a range of professional backgrounds, we identified 3 major objectives that will further the College's mission, along with the dual goals of promoting support for CV research and ensuring that U.S. patients have timely access to cutting-edge, high-quality, safe, and efficient CV care. These objectives include increasing the availability of funding for research, removing barriers to clinical research, and developing a learning health system. Grant (R01) increased by 6 to 8 years. For PhD investigators, the average age increased from 36 to 42 years, whereas for MDs, the average age increased from 38 to 45 years. Individuals with MD-PhDs, on average, now wait until they are 44, rather than 36 years of age, to achieve their first RO1 grant (2).
Increased funding for basic, translational, clinical, population, and health services research is critical to reinvigorate the enterprise, improve our ability to address critical questions, and promote investigation as a career opportunity for young investigators, all with the goal of advancing the understanding of CV disease and developing science-based strategies for Trial, was conducted to assess the effect of radial artery access on outcomes of women undergoing PCI (7).
It was terminated early because of a lower than expected event rate, but nevertheless, it highlighted the potential of the ACC's patient registries to function as a platform for randomized trials.
Clinical trials of the future must be more efficient and less costly, but also address a broad array of critical questions in populations more representative of those with or at risk of the condition under study.
To address these concerns, the "pragmatic clinical 
CONCLUSIONS
Much work lies ahead and the actions of many others will be needed to achieve our aims. The identification of these 3 objectives is just the first step in the pro- 
